Sagittarius Life Science Corp (TPEX:3205)
Taiwan
· Delayed Price · Currency is TWD 45.30
0.00 (0.00%)
At close: Dec 5, 2025
Sagittarius Life Science Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 424.44 | 467.75 | 440.46 | 529.07 | 587.61 | 558.19 | Upgrade
|
| Revenue Growth (YoY) | -6.78% | 6.20% | -16.75% | -9.96% | 5.27% | 27.23% | Upgrade
|
| Cost of Revenue | 349.57 | 386.64 | 368.98 | 446.5 | 487.07 | 448.32 | Upgrade
|
| Gross Profit | 74.87 | 81.11 | 71.48 | 82.56 | 100.54 | 109.86 | Upgrade
|
| Selling, General & Admin | 106.25 | 124.78 | 114.02 | 142.1 | 158.98 | 156.81 | Upgrade
|
| Research & Development | 22.11 | 17.89 | 21.83 | 22.69 | 31.58 | 24.86 | Upgrade
|
| Operating Expenses | 128.36 | 142.67 | 135.85 | 164.79 | 190.55 | 181.67 | Upgrade
|
| Operating Income | -53.49 | -61.56 | -64.38 | -82.23 | -90.01 | -71.8 | Upgrade
|
| Interest Expense | -0.12 | -0.21 | -0.08 | -0.23 | -0.39 | -0.33 | Upgrade
|
| Interest & Investment Income | 7.02 | 4.93 | 4.59 | 1.48 | 1.26 | 2.87 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -2.98 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.08 | 1.49 | -0.11 | 2.86 | -1.22 | -8.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.15 | 2.69 | 3.24 | 3.38 | 2.92 | 3.4 | Upgrade
|
| EBT Excluding Unusual Items | -46.52 | -52.66 | -56.75 | -77.72 | -87.45 | -74 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.13 | 2.98 | -0.08 | 0.01 | -0.01 | - | Upgrade
|
| Other Unusual Items | - | - | - | 1.21 | - | - | Upgrade
|
| Pretax Income | -45.89 | -49.68 | -56.82 | -76.5 | -87.46 | -74 | Upgrade
|
| Income Tax Expense | - | - | - | -0.01 | - | 0.49 | Upgrade
|
| Earnings From Continuing Operations | -45.89 | -49.68 | -56.82 | -76.49 | -87.46 | -74.49 | Upgrade
|
| Minority Interest in Earnings | -0.44 | 1.15 | 1.79 | 2.29 | 1.04 | 0.37 | Upgrade
|
| Net Income | -46.33 | -48.53 | -55.04 | -74.2 | -86.42 | -74.12 | Upgrade
|
| Net Income to Common | -46.33 | -48.53 | -55.04 | -74.2 | -86.42 | -74.12 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 33 | 33 | 33 | 33 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 33 | 33 | 33 | 33 | 33 | Upgrade
|
| Shares Change (YoY) | 39.00% | - | - | - | -0.22% | -0.47% | Upgrade
|
| EPS (Basic) | -1.02 | -1.49 | -1.69 | -2.28 | -2.66 | -2.27 | Upgrade
|
| EPS (Diluted) | -1.02 | -1.49 | -1.69 | -2.28 | -2.66 | -2.27 | Upgrade
|
| Free Cash Flow | -25.71 | -47.77 | -71.38 | -53.98 | -37.4 | -73.13 | Upgrade
|
| Free Cash Flow Per Share | -0.57 | -1.47 | -2.19 | -1.66 | -1.15 | -2.24 | Upgrade
|
| Gross Margin | 17.64% | 17.34% | 16.23% | 15.60% | 17.11% | 19.68% | Upgrade
|
| Operating Margin | -12.60% | -13.16% | -14.62% | -15.54% | -15.32% | -12.86% | Upgrade
|
| Profit Margin | -10.92% | -10.38% | -12.50% | -14.03% | -14.71% | -13.28% | Upgrade
|
| Free Cash Flow Margin | -6.06% | -10.21% | -16.21% | -10.20% | -6.37% | -13.10% | Upgrade
|
| EBITDA | -50.26 | -56.16 | -57.68 | -74.85 | -81.43 | -61.61 | Upgrade
|
| EBITDA Margin | -11.84% | -12.01% | -13.10% | -14.15% | -13.86% | -11.04% | Upgrade
|
| D&A For EBITDA | 3.23 | 5.4 | 6.7 | 7.38 | 8.59 | 10.2 | Upgrade
|
| EBIT | -53.49 | -61.56 | -64.38 | -82.23 | -90.01 | -71.8 | Upgrade
|
| EBIT Margin | -12.60% | -13.16% | -14.62% | -15.54% | -15.32% | -12.86% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.